Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Radiopharma firm ITM raises $109 million

by Ryan Cross
April 30, 2021 | A version of this story appeared in Volume 99, Issue 16

The German radiopharmaceutical company Isotopen Technologien München (ITM) has raised $109 million through a convertible loan financing to advance its cancer drug programs. ITM’s lead product is a radionucleotide that uses the peptide edotreotide to deliver lutetium-177 to cancer cells. The therapy, called Solucin, is in a Phase 3 clinical trial for people with neuroendocrine tumors. ITM also has preclinical programs pairing lutetium-177 with tumor-targeting molecules for other kinds of cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.